Advertisement
Advertisement
FDMT
4D Molecular Therapeutics, Inc. Common Stock
10.18
USDSponsored
+0.31
+3.16%
Mar 26, 15:59 UTC -4
Closed
Pre-Market
10.59
+0.41
+4.02%
FDMT Earnings Reports
Positive Surprise Ratio
FDMT beat 14 of 21 last estimates.
67%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.91M
/-$1.02
Implied change from Q4 25 (Revenue/ EPS)
-90.71%
/-337.21%
Implied change from Q1 25 (Revenue/ EPS)
+56364.29%
/+18.60%
4D Molecular Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 18, 2026, FDMT reported earnings of 0.43 USD per share (EPS) for Q4 25, beating the estimate of -0.77 USD, resulting in a 155.29% surprise. Revenue reached 85.09 million, compared to an expected 9.36 million, with a 808.73% difference. The market reacted with a -3.42% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -1.02 USD, with revenue projected to reach 7.91 million USD, implying an decrease of -337.21% EPS, and decrease of -90.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Vivani Medical, Inc. Common Stock (DE)
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.09
Surprise
-
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were 4D Molecular Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, 4D Molecular Therapeutics, Inc. Common Stock reported EPS of $0.43, beating estimates by 155.29%, and revenue of $85.09M, 808.73% above expectations.
How did the market react to 4D Molecular Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -3.42%, changed from $9.66 before the earnings release to $9.33 the day after.
When is 4D Molecular Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for 4D Molecular Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, 4D Molecular Therapeutics, Inc. Common Stock is expected to report EPS of -$1.02 and revenue of $7.91M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement